PT-141

PT-141 was originally developed as a sunless tanning agent derived from Melanotan II, but researchers discovered its potent pro-sexual effects during early human trials. It was subsequently developed as Bremelanotide and received FDA approval in June 2019 for HSDD in premenopausal women.

Its mechanism of action is unique among sexual health drugs — it activates melanocortin receptors in the central nervous system, particularly MC3R and MC4R in the hypothalamus, triggering the sexual arousal response at the neurological level rather than through peripheral blood flow changes. This makes it effective for both women with HSDD and men with psychogenic erectile dysfunction who do not respond adequately to PDE5 inhibitors.

The cyclic structure of PT-141 (a lactam bridge between Asp and Lys) confers resistance to enzymatic degradation and contributes to its selectivity for central melanocortin receptors over the MC1R (which mediates skin pigmentation).

// MELANOCORTIN RECEPTOR AGONISM

PT-141 acts as an agonist at MC3R and MC4R receptors in the hypothalamus and limbic system. MC4R activation in the medial preoptic area (MPOA) and paraventricular nucleus (PVN) is particularly critical — these areas regulate sexual motivation and arousal. Downstream dopaminergic signaling in the mesolimbic pathway amplifies the motivational component of sexual desire.

// CENTRAL vs. PERIPHERAL MECHANISM

Unlike PDE5 inhibitors (sildenafil, tadalafil) which work peripherally by increasing blood flow, PT-141 works upstream in the brain to initiate the sexual response. This explains its efficacy in individuals with psychogenic, rather than purely vascular, sexual dysfunction. It also means onset is not dependent on sexual stimulation for its initial central effect.

// SECONDARY MELANOCYTE STIMULATION

As an α-MSH analogue, PT-141 also stimulates MC1R to a degree, causing increased melanin synthesis with repeated dosing. This skin-darkening side effect, while manageable at therapeutic doses, was the primary finding in its original development as a tanning agent.

Phase 3 clinical trials (RECONNECT studies) demonstrated statistically significant improvements in satisfying sexual events (SSEs) and sexual desire scores in premenopausal women with HSDD. The drug is now FDA-approved under the name Vyleesi.

Research in men with erectile dysfunction has shown benefit particularly in non-responders to PDE5 inhibitors, with improvements in both erectile function and sexual desire. These indications remain off-label.

The most common adverse effects are nausea (40%), flushing (20%), and transient blood pressure elevation (mean +6 mmHg systolic). Pre-treatment with ondansetron is often used in research settings to mitigate nausea.